Medscape Medical News > Conference News Sulfonylurea Use Increases All-Cause Mortality Risk Michael
BARCELONA, Spain (updated September 27, 2013) — First-line therapy with sulfonylureas significantly increases the risk for death in patients with type 2 diabetes when compared with treatment with metformin, a new study shows. Additional research showed that the combination of metformin and a sulfonylurea was also associated with a significantly increased risk for death when compared with combination therapy with metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor (or "gliptin").